Nerviano Medical Sciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Nerviano Medical Sciences sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 3 currently recruiting 2 completed early-phase tilt top decile by trial count

Nerviano Medical Sciences: 11 sponsored US clinical trials, 3 recruiting.

Nerviano Medical Sciences sponsors 11 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diffuse Glioma, with 1 trials.

Top-decile sponsor footprint

Nerviano Medical Sciences ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 1

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

NCT06930755
RECRUITING Phase 1

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

NCT06931626
RECRUITING Phase 1

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06549790
ACTIVE NOT RECRUITING Phase 1

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

NCT04910022
TERMINATED Phase 1

Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma

NCT05027594
TERMINATED Phase 1

Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy

NCT05630937
TERMINATED Phase 1

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

NCT04182516
COMPLETED Phase 1

Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors

NCT01014429
TERMINATED Phase 1

Study of NMS-1116354 in Solid Tumors

NCT01016327
TERMINATED Phase 2

PHA-739358 for the Treatment of Multiple Myeloma

NCT00872300
COMPLETED Phase 1

Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors

NCT01300468

Phase Distribution

PhaseTrial count
Phase 1 10
Phase 2 1

Therapeutic Areas

Diffuse Glioma 1
Relapsed/Refractory Acute Myeloid Leukemia 1
Glioblastoma 1
Small-cell Lung Cancer 1
Ovarian Cancer 1

What is open in the Nerviano Medical Sciences pipeline

3 recruiting of 11 indexed (27% open); 2 completed (18%).

Phase mix: 0 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Diffuse Glioma (1 trial), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Nerviano Medical Sciences: open-pipeline peers nationwide

Peers matched on 11 registered trials and 27% open enrollment, not the therapeutic-area sidebar.

Nerviano Medical Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30% Total trials Recruiting share Nerviano Medical SciencesAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeConnecticut Children's Medical CenterCriteriumMinneapolis Heart Institute FoundationNeuronetics
Nerviano Medical Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Nerviano Medical Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 27% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Nerviano Medical Sciences page

11 registered trials is a research-attention snapshot, not an endorsement of Nerviano Medical Sciences or any single study.

  • 3 of Nerviano Medical Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Diffuse Glioma is the condition Nerviano Medical Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diffuse Glioma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Nerviano Medical Sciences pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.